Journal of Oncology

Review Article

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer

Table 2

Summary of completed and ongoing studies of neoadjuvant chemotherapy and targeted therapy in TNBC.


Study		Treatment	Primary endpoint

Platinum agents
Alba et al. [21]	94	EC^a followed by D^b versus EC followed by D plus Cb^c	pCR^h
Silver et al. [22]	28	Cisplatin	pCR
Sirohi et al. [23]	62	Cisplatin	Clinical response rates, OSⁱ
Kern et al. [24]	27	Carboplatin plus docetaxel	pCR
Tiley et al. [25]	12	AC^d followed by P^e with Cb	pCR
GeparSixto [26]	Ongoing	Carboplatin plus standard chemotherapy	pCR

Targeting angiogenesis
Ryan et al. [18]	51	Cisplatin plus bevacizumab	Clinical response
CALGB 40603 [26]	Ongoing	Carboplatin and/or bevacizumab	pCR
NCT00887575 [26]	Ongoing	Sunitinib plus pactlitaxel plus carboplatin	MTD^j, pCR
NCT01194869 [26]	Ongoing	Sorafenib plus pactlitaxel plus cisplatin	pCR

Targeting DNA damage repair
Llombart et al. [27]	141	Iniparib plus paclitaxel	pCR
NCT00813956 [26]	Ongoing	Gemcitabine plus Cb plus iniparib	pCR
I-SPY 2 [26]	Ongoing	Veliparib plus paclitaxel	pCR

Targeting EGFR
ICE [26]	Ongoing	Ixabepilone plus cetuximab	pCR
NCT00491816 [26]	Ongoing	Erlotinib plus chemotherapy	pCR

Targets HER3
NCT01421472	Ongoing	Paclitaxel plus MM-121 (targets HER3)	pCR

Targets inhibitors of apoptosis (IAP)
NCT01617668	Ongoing	Paclitaxel plus LCL161	pCR

Targets gamma-secretase/notch signaling pathway
NCT01238133	Ongoing	Paclitaxel plus Cb plus RO4929097	MTD

Targets PI3K/mTOR
Gonzalez-Angulo et al. [28]	62	T-FEC^f versus TR-FEC^g	Clinical response rate at 12 weeks
NCT00930930	Ongoing	Cisplatin plus paclitaxel ± everolimus	pCR

Targets multiple tyrosine kinases
NCT00817531	Completed	Dasatinib	Clinical response by RECIST

^aEpirubicin cyclophosphamide, ^bdocetaxel, ^ccarboplatin, ^ddoxorubicin cyclophosphamide, ^epaclitaxel, ^fpaclitaxel 5-flourouracil epirubicin cyclophosphamide, ^gpaclitaxel everolimus 5-flourouracil epirubicin cyclophosphamide, ^hpathologic complete response, ⁱoverall survival, ^jmaximum tolerated dose.